TY - JOUR
T1 - Natural history of meningioma development in mice reveals
T2 - A synergy of Nf2 and p16Ink4a mutations
AU - Kalamarides, Michel
AU - Stemmer-Rachamimov, Anat O.
AU - Takahashi, Masaya
AU - Han, Zhi Yan
AU - Chareyre, Fabrice
AU - Niwa-Kawakita, Michiko
AU - Black, Peter M.
AU - Carroll, Rona S.
AU - Giovannini, Marco
PY - 2008/1
Y1 - 2008/1
N2 - Meningiomas account for approximately 30% of all primary central nervous system tumors and are found in half of neurofibromatosis type 2 patients often causing significant morbidity. Although most meningiomas are benign, 10% are classified as atypical or anaplastic, displaying aggressive clinical behavior. Biallelic inactivation of the neurofibromatosis 2 (NF2) tumor suppressor is associated with meningioma formation in all NF2 patients and 60% of sporadic meningiomas. Deletion of the p16INK4a/p14ARF locus is found in both benign and malignant meningiomas, while mutation of the p53 tumor suppressor gene is uncommon. Previously, we inactivated Nf2 in homozygous conditional knockout mice by adenoviral Cre delivery and showed that Nf2 loss in arachnoid cells is rate-limiting for meningioma formation. Here, we report that additional nullizygosity for p16Ink4a increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade. In addition, by using magnetic resonance imaging (MRI) to screen a large cohort of mutant mice, we were able to detect meningothelial proliferation and meningioma development opening the way to future studies in which therapeutic interventions can be tested as preclinical assessment of their potential clinical application.
AB - Meningiomas account for approximately 30% of all primary central nervous system tumors and are found in half of neurofibromatosis type 2 patients often causing significant morbidity. Although most meningiomas are benign, 10% are classified as atypical or anaplastic, displaying aggressive clinical behavior. Biallelic inactivation of the neurofibromatosis 2 (NF2) tumor suppressor is associated with meningioma formation in all NF2 patients and 60% of sporadic meningiomas. Deletion of the p16INK4a/p14ARF locus is found in both benign and malignant meningiomas, while mutation of the p53 tumor suppressor gene is uncommon. Previously, we inactivated Nf2 in homozygous conditional knockout mice by adenoviral Cre delivery and showed that Nf2 loss in arachnoid cells is rate-limiting for meningioma formation. Here, we report that additional nullizygosity for p16Ink4a increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade. In addition, by using magnetic resonance imaging (MRI) to screen a large cohort of mutant mice, we were able to detect meningothelial proliferation and meningioma development opening the way to future studies in which therapeutic interventions can be tested as preclinical assessment of their potential clinical application.
UR - http://www.scopus.com/inward/record.url?scp=38349190206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38349190206&partnerID=8YFLogxK
U2 - 10.1111/j.1750-3639.2007.00105.x
DO - 10.1111/j.1750-3639.2007.00105.x
M3 - Article
C2 - 17924978
AN - SCOPUS:38349190206
SN - 1015-6305
VL - 18
SP - 62
EP - 70
JO - Brain Pathology
JF - Brain Pathology
IS - 1
ER -